8-K Announcements
6Material company update
Apr 10, 2026·SEC
Material company update
Mar 25, 2026·SEC
Material company update
Mar 24, 2026·SEC
Longeveron Inc.(LGVN)Earnings, Financials & Key Ratios
LGVN•NASDAQ
$0.86
$20M mkt cap·Price updated May 6, 2026
AboutLongeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.Show more
- Revenue$1M-49.9%
- EBITDA-$22M-41.7%
- Net Income-$23M-42.1%
- EPS (Diluted)-1.29-20.6%
- Gross Margin66.97%-15.0%
- EBITDA Margin-1839.87%-182.8%
- Operating Margin-1942.2%-181.2%
- Net Margin-1893.58%-183.6%
- ROE-164.75%-47.6%
- ROIC-588.06%-88.3%
- Debt/Equity0.15+119.6%
LGVN Key Insights
Longeveron Inc. (LGVN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 85 (top 15%)
✗Weaknesses
- ✗Profits declining 43.6% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Sales declining 26.6% over 5 years
- ✗Shares diluted 18.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
LGVN Price & Volume
Longeveron Inc. (LGVN) stock price & volume — 10-year historical chart
Loading chart...
LGVN Growth Metrics
Longeveron Inc. (LGVN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-26.6%
3 Years-0.63%
TTM-49.87%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-42.16%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM67.9%
Return on Capital
10 Years-88.95%
5 Years-107.42%
3 Years-134.22%
Last Year-159.77%
LGVN Peer Comparison
Longeveron Inc. (LGVN) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MESO | 2.04B | 15.79 | -18.80 | 191.39% | -5.94% | -17.1% | 0.21 | |
 NKTR | 1.65B | 84.16 | -8.65 | -43.89% | -192.87% | -356.81% | 0.95 | |
 BCLI | 6.97M | 0.69 | 0.31 | -13.48% | ||||
 PLUR | 214.19M | 3.38 | -0.95 | 309.82% | -19.98% | -9.93% | ||
 FATE | 272.25M | 2.36 | -2.05 | -51.24% | -20.51% | -65.79% | 0.38 | |
 CELH | 8.61B | 33.52 | 134.08 | 85.54% | 4.29% | 4.66% | 3.76% | 0.23 |
 RCEL | 129.62M | 4.24 | -2.44 | 11.45% | -67.85% | |||
 MDXG | 540.78M | 3.64 | 11.38 | 19.99% | 7.88% | 12.86% | 13.49% | 0.09 |
Compare LGVN vs Peers
Longeveron Inc. (LGVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LGVN Income Statement
Longeveron Inc. (LGVN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.13M | 5.63M | 5.63M | 1.31M | 1.22M | 709K | 2.39M | 1.2M |
| Revenue Growth % | - | 163.71% | -0.01% | -76.8% | -6.43% | -41.98% | 237.38% | -49.87% |
| Cost of Goods Sold | 1.45M | 3.8M | 3.8M | 716K | 725K | 488K | 508K | 396K |
| COGS % of Revenue | 68.12% | 67.56% | 67.56% | 54.82% | 59.33% | 68.83% | 21.24% | 33.03% |
| Gross Profit | 680.65K▲ 0% | 1.83M▲ 168.3% | 1.83M▼ 0.0% | 590K▼ 67.7% | 497K▼ 15.8% | 221K▼ 55.5% | 1.88M▲ 752.5% | 803K▼ 57.4% |
| Gross Margin % | 31.88% | 32.44% | 32.44% | 45.18% | 40.67% | 31.17% | 78.76% | 66.97% |
| Gross Profit Growth % | - | 168.31% | -0.01% | -67.69% | -15.76% | -55.53% | 752.49% | -57.38% |
| Operating Expenses | 7.04M | 5.6M | 5.6M | 18.05M | 18.54M | 21.25M | 18.41M | 24.09M |
| OpEx % of Revenue | 329.84% | 99.56% | 99.56% | 1381.78% | 1517.18% | 2997.18% | 769.48% | 2009.17% |
| Selling, General & Admin | 3.17M | 2.93M | 2.93M | 10.95M | 9.17M | 12.18M | 10.27M | 12.05M |
| SG&A % of Revenue | 148.28% | 52.05% | 52.05% | 838.74% | 750.41% | 1718.48% | 429.31% | 1004.92% |
| Research & Development | 3.88M | 2.67M | 2.67M | 7.09M | 9.37M | 9.07M | 8.14M | 12.04M |
| R&D % of Revenue | 181.56% | 47.51% | 47.5% | 543.03% | 766.78% | 1278.7% | 340.18% | 1004.25% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -6.36M▲ 0% | -3.78M▲ 40.6% | -3.78M▲ 0.0% | -17.46M▼ 362.0% | -18.04M▼ 3.4% | -21.03M▼ 16.5% | -16.52M▲ 21.4% | -23.29M▼ 40.9% |
| Operating Margin % | -297.95% | -67.12% | -67.12% | -1336.6% | -1476.51% | -2966.01% | -690.72% | -1942.2% |
| Operating Income Growth % | - | 40.6% | 0.01% | -362.04% | -3.36% | -16.55% | 21.43% | -40.95% |
| EBITDA | -5.61M | -3.01M | -2.99M | -16.54M | -17.15M | -20.08M | -15.56M | -22.06M |
| EBITDA Margin % | -263.02% | -53.46% | -53.17% | -1266.62% | -1403.44% | -2832.58% | -650.67% | -1839.87% |
| EBITDA Growth % | - | 46.4% | 0.55% | -452.69% | -3.68% | -17.1% | 22.5% | -41.74% |
| D&A (Non-Cash Add-back) | 745.77K | 768.84K | 785K | 914K | 893K | 946K | 958K | 1.23M |
| EBIT | -6.34M | -3.71M | -3.71M | -17.04M | -18.04M | -21.03M | -16.52M | -23.29M |
| Net Interest Income | 23.82K | 2.77K | -6.4K | -4K | 0 | 0 | 0 | 0 |
| Interest Income | 23.82K | 2.94K | 139 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 169 | 6.54K | 4K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 23.82K | 57.47K | 57K | 411K | -792K | -384K | 549K | 583K |
| Pretax Income | -6.34M▲ 0% | -3.72M▲ 41.3% | -3.72M▼ 0.0% | -17.05M▼ 358.1% | -18.84M▼ 10.5% | -21.41M▼ 13.7% | -15.97M▲ 25.4% | -22.7M▼ 42.1% |
| Pretax Margin % | -296.84% | -66.09% | -66.1% | -1305.13% | -1541.33% | -3020.17% | -667.77% | -1893.58% |
| Income Tax | 23.82K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.38% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -6.34M▲ 0% | -3.72M▲ 41.3% | -3.72M▼ 0.0% | -17.05M▼ 358.1% | -18.84M▼ 10.5% | -21.41M▼ 13.7% | -15.97M▲ 25.4% | -22.7M▼ 42.1% |
| Net Margin % | -296.84% | -66.09% | -66.1% | -1305.13% | -1541.33% | -3020.17% | -667.77% | -1893.58% |
| Net Income Growth % | - | 41.28% | -0.01% | -358.08% | -10.5% | -13.69% | 25.41% | -42.14% |
| Net Income (Continuing) | -6.34M | -3.72M | -3.72M | -17.05M | -18.84M | -21.41M | -15.97M | -22.7M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.98▲ 0% | -1.87▲ 53.0% | -2.21▼ 18.2% | -9.00▼ 307.2% | -9.00▲ 0.0% | -10.22▼ 13.6% | -1.07▲ 89.5% | -1.29▼ 20.6% |
| EPS Growth % | - | 53.02% | -18.18% | -307.24% | 0% | -13.56% | 89.53% | -20.56% |
| EPS (Basic) | -3.98 | -1.87 | -2.21 | -9.00 | -9.00 | -10.22 | -1.07 | -1.29 |
| Diluted Shares Outstanding | 1.59M | 1.6M | 1.69M | 1.89M | 2.1M | 2.17M | 14.89M | 17.58M |
| Basic Shares Outstanding | 1.59M | 1.6M | 1.69M | 1.89M | 2.1M | 2.17M | 14.89M | 17.58M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
LGVN Balance Sheet
Longeveron Inc. (LGVN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 4.16M | 2.37M | 1.85M | 35.38M | 20.28M | 5.85M | 19.62M | 5.45M |
| Cash & Short-Term Investments | 4.03M | 1.87M | 816K | 35.04M | 19.66M | 5.36M | 19.23M | 4.66M |
| Cash Only | 4.03M | 1.87M | 816K | 25.66M | 10.5M | 4.95M | 19.23M | 4.66M |
| Short-Term Investments | 0 | 0 | 0 | 9.38M | 9.15M | 412K | 0 | 0 |
| Accounts Receivable | 0 | 451.46K | 420K | 55K | 218K | 111K | 84K | 104K |
| Days Sales Outstanding | - | 29.27 | 27.23 | 15.37 | 65.11 | 57.14 | 12.82 | 31.66 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 561K | 0 | 404K | 376K | 308K | 686K |
| Total Non-Current Assets | 6.36M | 8.21M | 7.39M | 7.39M | 7.13M | 6.23M | 5.93M | 4.81M |
| Property, Plant & Equipment | 4.76M | 6.48M | 5.67M | 4.88M | 4.48M | 3.75M | 3.33M | 2.35M |
| Fixed Asset Turnover | 0.45x | 0.87x | 0.99x | 0.27x | 0.27x | 0.19x | 0.72x | 0.51x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.35M | 1.48M | 1.55M | 2.33M | 2.41M | 2.29M | 2.4M | 2.29M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100K |
| Other Non-Current Assets | 250.89K | 250.89K | 177K | 177K | 244K | 193K | 202K | 76K |
| Total Assets | 10.52M▲ 0% | 10.58M▲ 0.6% | 9.24M▼ 12.7% | 42.77M▲ 362.8% | 27.41M▼ 35.9% | 12.08M▼ 55.9% | 25.56M▲ 111.6% | 10.26M▼ 59.9% |
| Asset Turnover | 0.20x | 0.53x | 0.61x | 0.03x | 0.04x | 0.06x | 0.09x | 0.12x |
| Asset Growth % | - | 0.6% | -12.7% | 362.84% | -35.9% | -55.94% | 111.61% | -59.85% |
| Total Current Liabilities | 1.86M | 2.49M | 3.83M | 2.71M | 4.87M | 3.89M | 2.58M | 4.09M |
| Accounts Payable | 1.21M | 1.15M | 1.59M | 645K | 1.75M | 638K | 99K | 423K |
| Days Payables Outstanding | 302.57 | 110.82 | 152.6 | 328.81 | 881.54 | 477.19 | 71.13 | 389.89 |
| Short-Term Debt | 0 | 0 | 177K | 0 | 0 | 0 | 0 | 655K |
| Deferred Revenue (Current) | 405K | 541.79K | 10K | 199K | 506K | 506K | 40K | 40K |
| Other Current Liabilities | 209.26K | 0 | 0 | 0 | 1.4M | 0 | 0 | 2.97M |
| Current Ratio | 2.24x | 0.95x | 0.48x | 13.06x | 4.17x | 1.50x | 7.60x | 1.33x |
| Quick Ratio | 2.24x | 0.95x | 0.48x | 13.06x | 4.17x | 1.50x | 7.60x | 1.33x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.84M | 3.65M | 3.45M | 2.6M | 2.04M | 1.45M | 1.09M | 499K |
| Long-Term Debt | 0 | 0 | 311K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 3.65M | 3.14M | 2.6M | 2.04M | 1.45M | 824K | 169K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.84M | 0 | 0 | 0 | 0 | 0 | 265K | 330K |
| Total Liabilities | 3.71M | 6.14M | 7.28M | 5.31M | 6.91M | 5.34M | 3.67M | 4.59M |
| Total Debt | 0 | 4.14M | 4.14M | 3.14M | 2.6M | 2.04M | 1.45M | 824K |
| Net Debt | -4.03M | 2.27M | 3.33M | -22.52M | -7.9M | -2.91M | -17.79M | -3.84M |
| Debt / Equity | - | 0.93x | 2.12x | 0.08x | 0.13x | 0.30x | 0.07x | 0.15x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -21977.91x | -567.80x | -4260.25x | - | - | - | - |
| Total Equity | 6.81M▲ 0% | 4.45M▼ 34.8% | 1.96M▼ 56.0% | 37.45M▲ 1813.8% | 20.5M▼ 45.3% | 6.74M▼ 67.1% | 21.89M▲ 224.7% | 5.67M▼ 74.1% |
| Equity Growth % | - | -34.77% | -55.97% | 1813.8% | -45.26% | -67.12% | 224.68% | -74.07% |
| Book Value per Share | 4.28 | 2.78 | 1.16 | 19.80 | 9.78 | 3.10 | 1.47 | 0.32 |
| Total Shareholders' Equity | 6.81M | 4.45M | 1.96M | 37.45M | 20.5M | 6.74M | 21.89M | 5.67M |
| Common Stock | 7.11M | 0 | 1.96M | 21K | 21K | 2K | 14K | 22K |
| Retained Earnings | 0 | 0 | 0 | -43.94M | -62.77M | -84.98M | -109.61M | -132.31M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.39M | 0 | 0 | 0 | -357K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LGVN Cash Flow Statement
Longeveron Inc. (LGVN) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.18M | -2.39M | -2.36M | -9.64M | -13.97M | -19M | -13.87M | -18.64M |
| Operating CF Margin % | -242.57% | -42.47% | -42% | -737.83% | -1143.13% | -2680.11% | -579.77% | -1555.05% |
| Operating CF Growth % | - | 53.83% | 1.13% | -307.63% | -44.97% | -36.03% | 27.02% | -34.45% |
| Net Income | -6.34M | -2.96M | -3.72M | -17.05M | -18.84M | -21.41M | -15.97M | -22.7M |
| Depreciation & Amortization | 745.77K | 768.84K | 785.44K | 914K | 893K | 946K | 958K | 1.23M |
| Stock-Based Compensation | 423.87K | 136.85K | 83K | 7.74M | 2.17M | 2.03M | 2.33M | 1.68M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.9M | -120.13K | -167 | -155K | 1.57M | -603K | 60K | 97K |
| Working Capital Changes | -11.22K | -216.48K | 488.63K | -1.09M | 238K | 36K | -1.24M | 1.06M |
| Change in Receivables | 24.88K | -451.46K | 30.81K | 366K | -164K | 107K | 27K | -20K |
| Change in Inventory | 0 | 0 | -30.81K | -366K | 0 | 0 | 0 | 0 |
| Change in Payables | -13.09K | 0 | 130.94K | -945K | 1.11M | 0 | -540K | 325K |
| Cash from Investing | -211.68K | -125.05K | -261.5K | -10.7M | -677K | 8.19M | -640K | -595K |
| Capital Expenditures | -211.68K | -37.57K | -261.5K | -1.31M | -856K | -301K | -992K | -595K |
| CapEx % of Revenue | 9.92% | 0.67% | 4.65% | 100.31% | 70.05% | 42.45% | 41.47% | 49.62% |
| Acquisitions | 0 | 0 | 0 | 85K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -115.72K | -87.47K | 0 | -9.39M | 0 | 8.49M | 0 | 0 |
| Cash from Financing | 1.35M | 350K | 1.58M | 45.17M | -509K | 5.26M | 28.79M | 4.67M |
| Debt Issued (Net) | 0 | 0 | 488K | -188K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 1.1M | 45.81M | 2K | -174K | 12.87M | 4.98M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | -8.65M | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -174K | 0 | 0 |
| Other Financing | 1.35M | 350K | -12.67K | -451K | -511K | 5.44M | 24.57M | -311K |
| Net Change in Cash | -4.04M▲ 0% | -2.17M▲ 46.3% | -1.05M▲ 51.5% | 24.84M▲ 2465.7% | -15.15M▼ 161.0% | -5.55M▲ 63.4% | 14.28M▲ 357.2% | -14.57M▼ 202.0% |
| Free Cash Flow | -5.39M▲ 0% | -2.43M▲ 54.9% | -2.63M▼ 8.1% | -10.95M▼ 316.9% | -14.82M▼ 35.4% | -19.3M▼ 30.2% | -14.86M▲ 23.0% | -18.89M▼ 27.1% |
| FCF Margin % | -252.49% | -43.14% | -46.64% | -838.13% | -1213.18% | -2722.57% | -621.24% | -1575.48% |
| FCF Growth % | - | 54.95% | -8.11% | -316.93% | -35.44% | -30.21% | 23.02% | -27.12% |
| FCF per Share | -3.39 | -1.52 | -1.56 | -5.79 | -7.07 | -8.88 | -1.00 | -1.07 |
| FCF Conversion (FCF/Net Income) | 0.82x | 0.64x | 0.64x | 0.57x | 0.74x | 0.89x | 0.87x | 0.82x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LGVN Key Ratios
Longeveron Inc. (LGVN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -92.99% | -66.09% | -116.24% | -86.5% | -65% | -157.19% | -111.59% | -164.75% |
| Return on Invested Capital (ROIC) | -171.44% | -59.66% | -47.23% | -129.5% | -98.27% | -191.89% | -312.33% | -588.06% |
| Gross Margin | 31.88% | 32.44% | 32.44% | 45.18% | 40.67% | 31.17% | 78.76% | 66.97% |
| Net Margin | -296.84% | -66.09% | -66.1% | -1305.13% | -1541.33% | -3020.17% | -667.77% | -1893.58% |
| Debt / Equity | - | 0.93x | 2.12x | 0.08x | 0.13x | 0.30x | 0.07x | 0.15x |
| Interest Coverage | - | -21977.91x | -567.80x | -4260.25x | - | - | - | - |
| FCF Conversion | 0.82x | 0.64x | 0.64x | 0.57x | 0.74x | 0.89x | 0.87x | 0.82x |
| Revenue Growth | - | 163.71% | -0.01% | -76.8% | -6.43% | -41.98% | 237.38% | -49.87% |
LGVN SEC Filings & Documents
Longeveron Inc. (LGVN) SEC filings — annual & quarterly reports (10-K, 10-Q)
LGVN Frequently Asked Questions
Longeveron Inc. (LGVN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Longeveron Inc. (LGVN) reported $1.2M in revenue for fiscal year 2025. This represents a 44% decrease from $2.1M in 2018.
Longeveron Inc. (LGVN) saw revenue decline by 49.9% over the past year.
Longeveron Inc. (LGVN) reported a net loss of $22.7M for fiscal year 2025.
Dividend & Returns
Longeveron Inc. (LGVN) has a return on equity (ROE) of -164.7%. Negative ROE indicates the company is unprofitable.
Longeveron Inc. (LGVN) had negative free cash flow of $19.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More LGVN
Longeveron Inc. (LGVN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates